Effect of Spironolactone on Left Ventricular Mass and Aortic Stiffness in Early-Stage Chronic Kidney Disease A Randomized Controlled Trial

Nicola Edwards; Richard Steeds; Paul Stewart; Charles Ferro; Jonathan Townend

doi:10.1016/j.jacc.2009.03.066

Effect of Spironolactone on Left Ventricular Mass and Aortic Stiffness in Early-Stage Chronic Kidney Disease A Randomized Controlled Trial

Nicola Edwards, Richard Steeds, Paul Stewart, Charles Ferro, Jonathan Townend

Research output: Contribution to journal › Article

212 Citations (Scopus)

Abstract

Objectives We sought to determine whether the addition of spironolactone to angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) improves left ventricular mass and arterial stiffness in early-stage chronic kidney disease (CKD). Background Chronic kidney disease is associated with a high risk of cardiovascular disease and a high prevalence of left ventricular hypertrophy and arterial stiffness that confer an adverse prognosis. It is believed that these abnormalities are in part a result of activation of the renin-angiotensin-aldosterone system. Methods After an active run-in phase with spironolactone 25 mg once daily, 112 patients with stage 2 and 3 CKD with good blood pressure control (mean daytime ambulatory blood pressure

Original language	English
Pages (from-to)	505-512
Number of pages	8
Journal	Journal of the American College of Cardiology
Volume	54
Issue number	6
DOIs	https://doi.org/10.1016/j.jacc.2009.03.066
Publication status	Published - 1 Aug 2009

Keywords

spironolactone
renin-angiotensin-aldosterone system
arterial stiffness
left ventricular mass
chronic kidney disease

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jacc.2009.03.066

Cite this

@article{34365f4ce48f4ec6875e66da4bd61314,

title = "Effect of Spironolactone on Left Ventricular Mass and Aortic Stiffness in Early-Stage Chronic Kidney Disease A Randomized Controlled Trial",

abstract = "Objectives We sought to determine whether the addition of spironolactone to angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) improves left ventricular mass and arterial stiffness in early-stage chronic kidney disease (CKD). Background Chronic kidney disease is associated with a high risk of cardiovascular disease and a high prevalence of left ventricular hypertrophy and arterial stiffness that confer an adverse prognosis. It is believed that these abnormalities are in part a result of activation of the renin-angiotensin-aldosterone system. Methods After an active run-in phase with spironolactone 25 mg once daily, 112 patients with stage 2 and 3 CKD with good blood pressure control (mean daytime ambulatory blood pressure ",

keywords = "spironolactone, renin-angiotensin-aldosterone system, arterial stiffness, left ventricular mass, chronic kidney disease",

author = "Nicola Edwards and Richard Steeds and Paul Stewart and Charles Ferro and Jonathan Townend",

year = "2009",

month = aug,

day = "1",

doi = "10.1016/j.jacc.2009.03.066",

language = "English",

volume = "54",

pages = "505--512",

journal = "Journal of the American College of Cardiology",

publisher = "Elsevier",

number = "6",

}

TY - JOUR

T1 - Effect of Spironolactone on Left Ventricular Mass and Aortic Stiffness in Early-Stage Chronic Kidney Disease A Randomized Controlled Trial

AU - Edwards, Nicola

AU - Steeds, Richard

AU - Stewart, Paul

AU - Ferro, Charles

AU - Townend, Jonathan

PY - 2009/8/1

Y1 - 2009/8/1

N2 - Objectives We sought to determine whether the addition of spironolactone to angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) improves left ventricular mass and arterial stiffness in early-stage chronic kidney disease (CKD). Background Chronic kidney disease is associated with a high risk of cardiovascular disease and a high prevalence of left ventricular hypertrophy and arterial stiffness that confer an adverse prognosis. It is believed that these abnormalities are in part a result of activation of the renin-angiotensin-aldosterone system. Methods After an active run-in phase with spironolactone 25 mg once daily, 112 patients with stage 2 and 3 CKD with good blood pressure control (mean daytime ambulatory blood pressure

AB - Objectives We sought to determine whether the addition of spironolactone to angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) improves left ventricular mass and arterial stiffness in early-stage chronic kidney disease (CKD). Background Chronic kidney disease is associated with a high risk of cardiovascular disease and a high prevalence of left ventricular hypertrophy and arterial stiffness that confer an adverse prognosis. It is believed that these abnormalities are in part a result of activation of the renin-angiotensin-aldosterone system. Methods After an active run-in phase with spironolactone 25 mg once daily, 112 patients with stage 2 and 3 CKD with good blood pressure control (mean daytime ambulatory blood pressure

KW - spironolactone

KW - renin-angiotensin-aldosterone system

KW - arterial stiffness

KW - left ventricular mass

KW - chronic kidney disease

U2 - 10.1016/j.jacc.2009.03.066

DO - 10.1016/j.jacc.2009.03.066

M3 - Article

C2 - 19643310

VL - 54

SP - 505

EP - 512

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 6

ER -

Effect of Spironolactone on Left Ventricular Mass and Aortic Stiffness in Early-Stage Chronic Kidney Disease A Randomized Controlled Trial

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this